Outpatient Surgery Access Act of 2026
Summary
HR8091 is an early-stage bill with no market impact yet. It would improve Medicare ASC payment rates starting in 2027 by removing budget neutrality caps and tying updates to hospital outpatient rates. Pure-play ASC operators SGRY and SEM are the direct beneficiaries if the bill advances, but it remains in committee with a single sponsor and no appropriation mechanism.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8091 is a procedural Medicare payment modernization bill with no appropriated funds and no near-term market impact
- 2.Bill is stalled at committee referral — one sponsor, one cosponsor, no hearings, no Senate companion
- 3.If passed, pure-play ASC operators ($SGRY, $SEM) see the clearest revenue benefit from higher and uncapped Medicare rates starting 2027
- 4.No real price movement attributable to this bill — recent SGRY 30-day +17% and SEM +1.1% moves are sector/earnings driven
- 5.Enactment probability is low before 2027 given the election-year calendar and committee bandwidth
Market Implications
No measurable market implication from this bill at this time. $SGRY and current prices reflect company fundamentals and broader healthcare sector trends, not the probability of ASC payment reform. Should the bill receive a committee hearing or gain significant cosponsor momentum, the catalyst would be positive for ASC pure-plays. For now, this is a monitoring item only — no position changes warranted based on this legislation alone.
Full Analysis
-
What happened and its current status: Rep. Van Duyne (R-TX) introduced HR8091, the Outpatient Surgery Access Act of 2026, on March 25, 2026. It was referred to both the Energy and Commerce and Ways and Means Committees. The bill is in early committee-stage with no floor votes, hearings, or markups. Only one cosponsor (Rep. Larson, D-CT) has joined. There is no companion bill in the Senate. Legislative velocity is low — four actions all on the introduction date.
-
The money trail: This bill authorizes a change to Medicare payment methodology — it does NOT appropriate any funds. Starting in 2027, CMS would be required to update ASC payment rates using the same inflation factor applied to hospital outpatient departments (OPD fee schedule increase factor). The bill also prohibits CMS from applying budget neutrality adjustments exclusively to ASC services (which previously functioned as a hidden cap on ASC spending growth). Actual dollar impact depends on future OPD update factors; there is no fixed dollar amount in the legislation.
-
Structural winners and losers: Pure-play ASC operators Surgery Partners ($SGRY, ~100% ASC revenue) and Select Medical (, ~20-25% from ASCs) are the most directly positioned to benefit because Medicare ASC payments constitute a significant portion of their surgical volume revenue. Hospital-centric operators like Tenet ($THC, through USPI JV) see a net positive but diluted exposure. HCA ($HCA, heavy hospital outpatient footprint) could face modest competitive pressure if ASCs become more financially attractive for procedures that can shift sites of care.
-
Market data and price trends: As of April 30, 2026, $SGRY trades at $13.95, up 17.03% over 30 days but down 2.72% in the last 7 days. trades at $16.47, up 1.1% over 30 days. These moves are more likely driven by earnings expectations and broader sector trends rather than this early-stage bill, which has no discernible price catalyst yet. Both stocks remain well within their 52-week ranges.
-
Timeline: The bill must pass both committees (Energy & Commerce and Ways & Means), clear the House floor, pass the Senate, and be signed into law. With a single Republican sponsor and one Democratic cosponsor, bipartisan interest exists but legislative bandwidth for procedural Medicare payment changes in an election year is limited. Earliest possible effective date is January 2027 per the bill text. Near-term probability of enactment is low.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
removal of ASC-specific budget neutrality caps and alignment of Medicare annual payment updates for ambulatory surgical centers with hospital outpatient department (OPD) fee schedule increases
Who must act
Centers for Medicare & Medicaid Services (CMS)
What happens
CMS must calculate ASC payment updates using the OPD fee schedule increase factor starting in 2027 and cannot apply a budget neutrality adjustment solely to ASC services; this is expected to produce higher annual payment rate increases for ASCs compared to current law, and eliminate a regulatory mechanism that previously capped aggregate ASC expenditure growth relative to a baseline
Stock impact
Surgery Partners derives nearly all revenue from ASC operations; higher Medicare payment rates directly improve per-case reimbursement margins across its owned and managed centers, with no offsetting hospital revenue exposure
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
MURNANE BUILDING CONTRACTORS, INC.: $32.9M General Services Administration Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Veterans SPORT Act
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.